Reducing the Incidence of Incisional Hernia After Stoma Closure Using a Prophylactic Mesh
Launched by UNIVERSITY HOSPITAL, GENEVA · Aug 9, 2020
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying whether using a special mesh during the closure of stomas (which are openings created surgically for waste to leave the body) can help prevent incisional hernias. An incisional hernia can occur at the site of the stoma closure, and early studies suggest that applying this mesh may lower the chances of developing one. The trial will involve cancer patients who are having their ileostomy or colostomy closed and will compare those who receive the mesh with those who do not to see if it makes a difference over one year.
To participate in this study, patients must be adults who have had an ileostomy or colostomy due to digestive cancer and are planning to have it closed. They will need to provide informed consent to join. However, people who are allergic to the mesh, those taking certain medications that weaken the immune system, or those who cannot follow the study's procedures will not be eligible. By participating, patients may help improve the quality of life for themselves and others by contributing to important research on preventing hernias after stoma closure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patient
- • Ileostomy or colostomy performed during surgery for digestive cancer
- • Planned elective closure of ileostomy or colostomy
- • Informed written consent
- Exclusion Criteria:
- • Allergy to the mesh
- • Patients under corticosteroids or other immunosuppressive treatment
- • Inability/refusal to follow the procedures of the study
About University Hospital, Geneva
The University Hospital of Geneva is a leading academic medical center committed to advancing healthcare through innovative research and clinical excellence. Renowned for its multidisciplinary approach, the hospital integrates cutting-edge medical research with high-quality patient care, fostering a collaborative environment that encourages the translation of scientific discoveries into practical treatments. As a prominent sponsor of clinical trials, the University Hospital of Geneva is dedicated to exploring new therapies and improving patient outcomes, while adhering to the highest ethical standards and regulatory compliance. Its robust infrastructure and expert clinical teams ensure the efficient execution of trials across various medical specialties, contributing significantly to the advancement of global health initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Geneva, , Switzerland
Patients applied
Trial Officials
Nicolas Buchs, MD, PD
Study Director
University Hospitals of Geneva
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials